KRKA, d.d., Novo mesto (batch control and batch release) / KRKA, d.d., Novo mesto (secondary packaging)

Ukraine

All drugs from this manufacturer

  • ERLOTINIB KRKA

    The drug is used for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, for maintenance therapy, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.

    Dosage form: tablets, film-coated

    Active substance Dosage
    erlotinib 25 mg

    ATC: L01EB02

  • The drug is used for the treatment of non-small cell lung cancer (as first-line therapy in the presence of certain mutations, for maintenance therapy, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.

    Dosage form: tablets, film-coated

    Active substance Dosage
    erlotinib 100 mg

    ATC: L01EB02

  • The drug is used for the treatment of non-small cell lung cancer (as first-line therapy, for maintenance therapy, or after ineffective chemotherapy) and for the treatment of metastatic pancreatic cancer in combination with gemcitabine.

    Dosage form: tablets, film-coated

    Active substance Dosage
    erlotinib 150 mg

    ATC: L01EB02